Industry Insights 03 Jan 2026 views ( )

Parse Biosciences Launches Evercode Whole Blood Fixation

Parse Biosciences, a leading provider of accessible and scalable single-cell sequencing solutions, today announced the launch of Evercode? Whole Blood Fixation, a new kit enabling immediate stabilization of whole blood directly at the point of sample collection. This technology eliminates the need for on-site peripheral blood mononuclear cell (PBMC) isolation, specialized equipment, or trained personnel, allowing translational hematology and drug development teams to seamlessly collect blood samples in real-world clinical settings for downstream single-cell analysis.

In translational research, traditional single-cell RNA profiling workflows face a dilemma: either process fresh samples—prone to rapid degradation and requiring expert handling—or use fixation methods that capture only partial transcriptomes and fail to provide paired T-cell receptor (TCR) sequences. Additionally, isolating fresh PBMCs requires complex procedures and specialized reagents. Evercode Whole Blood Fixation overcomes these limitations while maintaining the comprehensive, unbiased transcriptome coverage characteristic of the Evercode platform, delivering a practical, scalable, high-quality single-cell RNA sequencing solution tailored for translational research.

Charlie Roco, Ph.D., Chief Technology Officer and Co-founder of Parse Biosciences, said: "We are excited about the new possibilities this technology unlocks for researchers in hematology, biomarker discovery, and translational medicine. By stabilizing samples at the moment of collection, Evercode Whole Blood Fixation preserves high-quality transcriptomes for rigorous downstream analysis, bringing the power of single-cell sequencing directly to blood-related research."

The new Whole Blood Fixation kit will begin shipping the week of December 8. For more information, visit Parse Biosciences at booth 1480 during the American Society of Hematology (ASH) Annual Meeting in Orlando or visit their website.

About Parse Biosciences

Parse Biosciences is a global life sciences company dedicated to accelerating human health and scientific discovery. The company empowers researchers to perform single-cell sequencing at unprecedented scale and convenience, driving breakthrough advances in cancer therapy, tissue regeneration, stem cell treatments, kidney and liver diseases, brain development, and immunology.

Leveraging technology developed by co-founders Alex Rosenberg and Charles Roco at the University of Washington, Parse has raised over $100 million and serves approximately 3,000 customers worldwide. Its growing product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and Trailmaker, an interactive data analysis solution.

Headquartered in Seattle's vibrant South Lake Union neighborhood, Parse recently expanded into a new headquarters and state-of-the-art laboratory facility. For more information, please visit .

Disclaimer: This content is for informational purposes only and does not reflect the views of this site. For accurate details, please refer to the official release from the brand.